Rubraca Gets FDA Approval for Prostate Cancer!

PCEC is so happy to announce that the U.S. Food and Drug Administration (FDA) approved rucaparib, a new medication to treat patients with a BRCA mutation for advanced prostate cancer. Medical advancements like these are what continue to inspire and bring hope to everyone in the fight against prostate cancer!  Click below to learn more.

Rubraca gets FDA Approval for Prostate Cancer

If you are interested in learning more about the BRCA mutation and prostate cancer treatment check out BRCABlue.com!

BRCA Blue

 Screen Shot 2020 04 20 at 4.15.58 PM

 

The real bottom line: this is not just a man’s disease. It’s a couple’s disease. It takes two to conquer it. But the love can, and will, and life will go on!”

~Janet Buss, wife of prostate cancer survivor Norm Buss

Join Our Newsletter

btn amazon